Cas:118909-22-1 UNII:4401EF6U24 manufacturer & supplier

Chemical Name:UNII:4401EF6U24

CAS.NO:118909-22-1

Synonyms:9-Amino-1,2,3,4-tetrahydroacridin-1-ol (2Z)-but-2-enedioate (1:1);1-Acridinol, 9-amino-1,2,3,4-tetrahydro-, (2Z)-2-butenedioate (1:1) (salt);UNII:4401EF6U24;UNII:WR9885GALS;UNII:YY1JW04JCB;9-amino-1,2,3,4-tetrahydro-acridin-1-ol, maleate;9-Amino-1,2,3,4-tetrahydro-1-acridinol (2Z)-2-butenedioate (1:1)

Molecular Formula:C₁₇H₁₈N₂O₅

Molecular Weight:330.335

HS Code:2933990090

Physical and Chemical Properties:

Melting point:171-173ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:133.74000

Exact Mass:330.121582

LogP:2.47970

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 9-Amino-1,2,3,4-tetrahydroacridin-1-ol (2Z)-but-2-enedioate (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-Amino-1,2,3,4-tetrahydro-1-acridinol (2Z)-2-butenedioate (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-Amino-1,2,3,4-tetrahydro-1-acridinol (2Z)-2-butenedioate (1:1) Use and application,1-Acridinol, 9-amino-1,2,3,4-tetrahydro-, (2Z)-2-butenedioate (1:1) (salt) technical grade,usp/ep/jp grade.

Related News: The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. UNII:4401EF6U24 manufacturer We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. UNII:4401EF6U24 supplier The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances. UNII:4401EF6U24 vendor ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� UNII:4401EF6U24 factory ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.��